Utah Cancer Specialists

Last Updated September 1, 2021

Protoccol Number
BRE009 Breast A Phase III Randomised Study Assessing the Efficacy andSafety of Study Drug+ Paclitaxel Versus Placebo + Paclitaxel as First-lineTreatment for Patients with Locally Advanced (Inoperable) or Metastatic ER PR negative HER2+ Triple Negative Breast Cancer NCT03997123
BRE010 Breast A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Study Drug Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer NCT03961698
BRE011 Breast A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Study Drug plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy NCT04752332
COL001 Colorectal A Multi-Center, Open-Label, Phase 2 Study to Evaluate Safety and Efficacy of U3-1402 In Subjects with Advanced or Metastatic Colorectal Cancer NCT04479436
GAL001 Gallbladder A Phase 3, Open-Label, Randomized Study of Study Drug Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of
Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
GAS004 Gastric A Phase 2 Randomized, Multicenter,  Study Drug and Chemotherapy Versus Placebo with Study Drug and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous,Non-Small Cell Lung Cancer (NSCLC) NCT04265534
GAS003 Gastric A Phase 3 Double-Blind, Randomized Study Drug Plus CAPOX Compared with Placebo Plus CAPOX as 1 Line Treatment of Subjects with Claudin18.2+, HER2-Phase 2/3 Trial to Evaluate Study Drug in Combination With Study Drug and Chemotherapy or Study Drug and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer NCT04082364
GAS002 Gastric A Phase 3 Double-Blind, Randomized Study Drug Plus CAPOX Compared with Placebo Plus CAPOX as 1 L Treatment of Subjects with Claudin18.2+, HER2-Negative,Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction NCT03653507
MUL001 Multiple Myeloma A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in combination with Daratumumab Compared with Daratumumab in Patients with Relapsed or Relapsed-Refractory Multiple Myeloma NCT04649060
MYE001 Myelofibrosis A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of a Study Drug Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis NCT03222609
HEA001 Head and Neck A phase 3 Study of a Study Drug in Combination with Paclitaxel, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT04338399
HEA002 Head and Neck Phase 3 study of Study Drug in combination with platinum-based chemotherapy and standard fractionation intensity modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck NCT04459715
LYM005 CLL-SLL-NHL A Phase 1/2 Study of Study Drug in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) NCT03740529
LYM004 Lymphona  A Study ofStudy Drug Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed-Refractory, Follicular Lymphoma Grade 1 to 3a or RR Marginal Zone Lymphoma NCT04680052
LUN006 Lung NSCLC Phase 3 Randomized Study of Study DrugVersus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations  NCT0465652
LUN005 Lung NSCLC A Randomized, Open-label Phase 3 Study of Combination of Study Drug Therapies Compared with Carboplatin-Pemetrexed, in Patients with  EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT04538664
LUN004 Lung SCLC  A Phase 3, Open-label,Randomized Study of a Drug Administered Sequentially with a Platinum Doublet or a Platinum Doublet Plus Study Drug in Third-
Line or Beyond Small Cell Lung Cancer
MEL001 Melanoma A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Study Drug and Nivolumab Versus Nivolumab Alone, After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12) NCT04410445
MDS001 MDS High Risk A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Study Drug in Combination with Study Drug in Patients Newly Diagnosed with Higher-Risk MyelodysplasticSyndrome (Higher-Risk MDS) NCT04401748
PAN002 Pancreas A Phase 2 study to Assess the Antitumor Activity and Safety of Study Drug in Combination with another Study Drug as First Line Treatment in Subjects with Claudin 18.2 CLDN18.2 Positive, Metastatic Pancreatic Adenocarcinoma NCT03816163
PAN001 Pancreas A phase III study of irinotecan liposome injection, oxaliplatin, 5-FU/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas NCT04083235
PRO003 Prostate A Phase 3 Randomized, Placebo-controlled, Double-blind Study of a Drug in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Predisone for Treatment of Subjects with Metastatic Prostate Cancer NCT03748641
STA005 Advanced Solid Tumor A Phase 2 Study of a Drug in Combination Therapies in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm)
and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer
STA006 Solid Tumor A Phase 1/2 Study of  a New Investigatinal Combination drug in Subjects With Advanced Solid Tumors NCT03861793
STA007 Solid Tumor A Phase 2 Study of a Drug in Combination Therapies in Participants with Neuregulin-1 (NGR1) Fusion Positive Locally Advanced or Metastatic Solid Tumors NCT04383210
URO001 Urothelial A Phase 1 Study of a Study Drug  in Combination with other Anticancer Therapies for the Treatment of Urothelial Cancer NCT03288545
NonThera001 Solid Tumor Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors N/A
Non Thera002 Liquid Tumor  An Observational Study to Collect and Assess Tissue Samples From Subjects with Documented Hematologic Malignancy N/A